Valtecne (VLT) H1 2025 earnings summary

Executive summary

• Consolidated revenue for H1 2025 reached €19.4 million, with EBITDA at €4.6 million and net profit at €1.9 million, following the acquisition of Utilità S.r.l.

• The medical business line now represents 75% of total sales, reflecting a strategic focus and portfolio expansion.

• Standalone revenue for the parent company declined 3.9% year-over-year, but production value increased 7.7%.

Financial highlights

• Consolidated EBITDA margin was 22.6%, with adjusted EBITDA margin at 26.9%.

• Net financial debt at June 30, 2025, was €0.9 million, up from €0.5 million at year-end 2024.

• Standalone net profit was €2.1 million, down 6% year-over-year; consolidated net profit was €1.9 million.

• Standalone EBITDA margin decreased to 21.7% from 23.7% a year earlier.

• Standalone net financial debt rose to €0.9 million from a cash-positive €6.8 million at year-end 2024, mainly due to the Utilità acquisition and dividend payout.

Outlook and guidance

• The medical segment is expected to grow double digits in production value for FY25, with the business mix shifting further toward medical.

• The industrial segment shows early signs of stabilization, while aerospace is experiencing positive momentum.

• Overall group volumes are expected to contract slightly for FY25, but profitability should remain close to FY24 levels.